RT Journal Article
T1 Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature.
A1 Delgado-Fernández, Marcial
A1 García-Gemar, Gracia Mar
A1 Fuentes-López, Ana
A1 Muñoz-Pérez, Manuel Isidro
A1 Oyonarte-Gómez, Salvador
A1 Ruíz-García, Ignacio
A1 Martín-Carmona, Jessica
A1 Sanz-Cánovas, Jaime
A1 Castaño-Carracedo, Manuel Ángel
A1 Reguera-Iglesias, José María
A1 Ruíz-Mesa, Juan Diego
K1 Convalescent plasma
K1 Covid-19
K1 Humoral immunodeficiency
K1 Inmunodeficiencia humoral
K1 Obinutuzumab
K1 Plasma de convalecientes
K1 Rituximab
AB Patients lacking humoral response have been suggested to develop a less severe COVID-19, but there are some reports with a prolonged, relapsing or deadly course. From April 2020, there is growing evidence on the benefits of COVID-19 convalescent plasma (CCP) for patients with humoral immunodeficiency. Most of them had a congenital primary immunodeficiency or were on treatment with anti CD20 antibodies. We report on three patients treated in our hospital and review thirty-one more cases described in the literature. All patients but three resolved clinical picture with CCP. A dose from 200 to 800ml was enough in most cases. Antibody levels after transfusion were negative or low, suggesting consumption of them in SARS-CoV-2 neutralization. These patients have a protracted clinical course shortened after CCP. CCP could be helpful for patients with humoral immunodeficiency. It avoid relapses and chronification. CCP should be transfused as early as possible in patients with COVID-19 and humoral immunodeficiency.
YR 2021
FD 2021-02-11
LK http://hdl.handle.net/10668/22166
UL http://hdl.handle.net/10668/22166
LA en
LA es
DS RISalud
RD Apr 5, 2025